The Modulo Bio team with CEO Michael Horowitz (fourth from right in semicircle)

Ex­clu­sive: With $8M, neu­ro start­up Mod­u­lo Bio emerges to test small mol­e­cules for ALS, de­men­tia in CEO’s per­son­al mis­sion

Em­bark­ing on a per­son­al mis­sion af­ter his best friend’s moth­er was di­ag­nosed with a mu­ta­tion-dri­ven case of fron­totem­po­ral de­men­tia, Michael Horowitz has pulled to­geth­er $8 mil­lion in ven­ture fund­ing at Mod­u­lo Bio to cre­ate small mol­e­cules for neu­rode­gen­er­a­tive dis­eases.

The San Diego and Bay Area biotech will se­lect its lead de­vel­op­ment can­di­date and some back­up op­tions with­in six months and then raise a Se­ries A to in­ves­ti­gate ther­a­peu­tics for C9orf72 mu­ta­tion-dri­ven cas­es of ALS and fron­totem­po­ral de­men­tia, Horowitz told End­points News.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.